trial · primary record
Mitapivat Matched Placebo
Transfusion-dependent Alpha-Thalassemia
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2032-06 |
| Primary endpoint | Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) Through Week 48 |
| Registry ID | NCT07506863 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:49.436Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07506863
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mitapivat Matched Placebo · compound